• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

First-time generic approvals

News
Article

Potassium iodide oral solution 65 mg/mL

Potassium iodide oral solution 65 mg/mL (equiv to Thyrosafe tablets 65 mg)
FLEMING & COMPANY

Terconazole vaginal cream 0.4% (equiv to Terazole 7 Vaginal Cream)
TARO

Estradiol transdermal system 0.025 mg/d and 0.075 mg/d (equiv to Climara)
MYLAN

Levofloxacin tablets 750 mg (equiv to Levaquin tablets)
TEVA

Desmopressin nasal solution 0.01% (equiv to DDAVP nasal spray)
APOTEX

Fentanyl transdermal systems 25 mcg/h, 50 mcg/h, 75 mcg/h, and 100 mcg/h (equiv to Duragesic transdermal systems)
MYLAN

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.